Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Alemtuzumab

Alemtuzumab is the antibody to the CD52 receptor present on B and T lymphocytes. The pharmacokinetics of alemtuzumab demonstrate a terminal half-life of 7 days. Alemtuzumab has shown clinical activity in the treatment of chronic lymphocytic leukemia. Severe and prolonged (6 months) immunosuppression may result, which necessitates prophylaxis with cotrimox-azole and antivirals to prevent opportunistic infections. [Pg.1294]

Alemtuzumab Infusion-reactions fever, chills, nausea, vomiting rash Antiviral and PCP prophylaxis should be initiated... [Pg.1420]

Combination therapy may provide improvement in longterm disease-free survival. The combination of fludarabine, cyclophosphamide, and rituximab improves CR rates compared with fludarabine alone (70% versus 20%) but at the expense of increased infections.28,29 Combinations of fludarabine and alemtuzumab are also being investigated, with the hope of improving overall survival.21... [Pg.1420]

Watch for infusion reactions with rituximab and alemtuzumab. Premedicate with acetaminophen and diphenhydramine to prevent these reactions. [Pg.1424]

Prophylactic trimethoprim-sulfamethoxazole is recommended for all patients receiving alemtuzumab. [Pg.1424]

Mabcampath (EU) or Campath (USA) alemtuzumab a humanized monoclonal antibody directed against CD52 surface antigen of B-lymphocytes) Millennium ILEX (EU) Berlex, ILEX Oncology Millennium Pharmaceuticals (USA) Chronic lymphocytic leukaemia... [Pg.381]

Alemtuzumab (Campath) MoAb to CD52 Third-line B-CLL Phase II... [Pg.447]

The three monoclonal antibodies approved, noted in Table 23.1, in the last 7 years for treatment of patients with cancer include Alemtuzumab (Campath M) (Genzyme Corporation, Cambridge, MA, U.S.A.), Cetuzimab (Erbitux ) (ImClone Corporation, Branchburg, NJ, U.S.A.), and bevacizumab (Avastin ) (Genentech, South San Francisco, CA, U.S.A.). [Pg.449]

CamPath Alemtuzumab ILEX, Pharmaceuticals Millenium, Cambrige, MA Anti-CD52 Chronic lymphocytic leukemia 2001... [Pg.580]

Alemtuzumab Campath Humanized IgGltc anti-CD52 Chronic lymphocytic leukemia 2001 United States... [Pg.114]

Examples of antibodies in the market include trastuzumab (anti-HER2 monoclonal antibody), rituximab, natalizumab (x4-integiin antibody), abciximab, infiximab (targets TNF-a in Crohn s disease and rheumatoid arthritis), alemtuzumab, adalimumab (TNF-a antibody for the treatment of rheumatoid arthritis) and efalizumab (anti-CDlla monoclonal antibody for the treatment of psoriasis)Rituximab is a mouse/human chimeric anti-CD20 monoclonal antibody used for the treatment of various l)unphoid malignancies. As CE)20 antigen is found on the surface of... [Pg.59]

Alemtuzumab Chronic lymphocytic leukaemia, multiple sclerosis... [Pg.62]

Alemtuzumab is a recombinant DNA-derived humanized monoclonal antibody used in the treatment of chronic lymphocytic leukemia and T-cell lymphoma. It targets CD52, a protein present on the surface of mature lymphocytes. Alemtuzumab has been associated with infusion-related events including hypotension, rigors, fever, shortness of breath, bron-chospasm, chills, and/or rash. Also reported were syncope, pulmonary infiltrates, cardiac arrhythmias, myocardial infarction and cardiac arrest. [Pg.461]

CD3 (muromonab-CD3), CD20 (Ritux-imab), CD25 (Basiliximab Daclizumab), CD33- (Gemtuzumab-ozogamicin), CD52 (Alemtuzumab)... [Pg.32]

Pharmacokinetics The pharmacokinetic profile of alemtuzumab was studied in a rising-dose trial in non-Hodgkin s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Campath was administered once weekly for a maximum of 12 weeks. Following intravenous infusions over a range of doses, the maximum serum concentration (C ax) and the area under the curve (AUC) showed relative dose pro-... [Pg.300]

Alemtuzumab, anti-CD52 humanized monoclonal antibody, CHO product... [Pg.447]

Alemtuzumab has shown impressive results in refractory or relapsed CLL as well as up-front therapy for untreated CLL (35). The use of alemtuzumab to eradicate minimal residual disease of CLL is also reasonable (36). The role of Fey receptor polymorphisms on the clinical activity of alemtuzumab for CLL has not been extensively studies and will be discussed later. [Pg.211]

See other pages where Alemtuzumab is mentioned: [Pg.603]    [Pg.619]    [Pg.590]    [Pg.1294]    [Pg.1420]    [Pg.512]    [Pg.513]    [Pg.581]    [Pg.604]    [Pg.583]    [Pg.606]    [Pg.218]    [Pg.61]    [Pg.722]    [Pg.299]    [Pg.299]    [Pg.300]    [Pg.500]    [Pg.555]    [Pg.204]    [Pg.210]    [Pg.210]    [Pg.210]    [Pg.211]    [Pg.220]   
See also in sourсe #XX -- [ Pg.1294 ]

See also in sourсe #XX -- [ Pg.59 , Pg.61 ]

See also in sourсe #XX -- [ Pg.447 , Pg.707 ]

See also in sourсe #XX -- [ Pg.299 ]

See also in sourсe #XX -- [ Pg.204 , Pg.210 ]

See also in sourсe #XX -- [ Pg.118 ]

See also in sourсe #XX -- [ Pg.574 ]

See also in sourсe #XX -- [ Pg.578 ]

See also in sourсe #XX -- [ Pg.68 , Pg.73 , Pg.87 , Pg.312 , Pg.318 ]

See also in sourсe #XX -- [ Pg.3 ]

See also in sourсe #XX -- [ Pg.156 , Pg.178 ]

See also in sourсe #XX -- [ Pg.5 , Pg.5 , Pg.229 , Pg.231 , Pg.232 ]

See also in sourсe #XX -- [ Pg.187 ]

See also in sourсe #XX -- [ Pg.54 , Pg.347 ]

See also in sourсe #XX -- [ Pg.352 ]

See also in sourсe #XX -- [ Pg.140 ]

See also in sourсe #XX -- [ Pg.573 ]



SEARCH



Alemtuzumab disorders

Alemtuzumab dosing

Alemtuzumab for

Alemtuzumab infection risk

Alemtuzumab infusion reaction

Alemtuzumab multiple sclerosis

Alemtuzumab toxicity

Cancer treatments alemtuzumab

Chronic lymphocytic leukemia Alemtuzumab

© 2024 chempedia.info